Aravind S. Kumar-Ravi

305 Grattan Street
Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Prostate Cancer Working Group 4 Recap.

Prostate Cancer Working Group 4 Recap.

Journal: European urology focus

Published: March 16, 2026

Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.

Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: March 16, 2026

[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.

[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.

Journal: The Lancet. Oncology

Published: October 07, 2025

Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.

Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.

Journal: The Lancet. Oncology

Published: August 07, 2025

Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.

Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: July 07, 2025

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.

Journal: The Lancet. Oncology

Published: April 17, 2025

Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.

Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 06, 2025

Peptide receptor radionuclide therapy in malignant insulinoma.

Peptide receptor radionuclide therapy in malignant insulinoma.

Journal: Endocrine-related cancer

Published: January 18, 2025

Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.

Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: August 19, 2024

Peptide receptor radionuclide therapy for ectopic Cushing's syndrome caused by metastatic neuroendocrine neoplasms.

Peptide receptor radionuclide therapy for ectopic Cushing's syndrome caused by metastatic neuroendocrine neoplasms.

Journal: Endocrine oncology (Bristol, England)

Published: April 16, 2024

Unraveling the Impact of 177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation.

Unraveling the Impact of 177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 25, 2023

Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.

Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.

Journal: European urology

Published: September 14, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026